SAMM50 and neoplasm: Furthermore, the analysis of TRG distribution following neoadjuvant CRT also showed that BRAFV600E-mutant patients exhibited higher proportions of TRG2 (52.94% vs. 28.57%) and TRG3 (17.65% vs. 6.28%), and lower proportions of TRG0 (0% vs. 15.37%) and TRG1 (5.88% vs. 12.77%), indicating a poorer local tumor regression response to neoadjuvant CRT compared to wild-type patients (Fig. 1K).